About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials | 6,584 Studies Recruiting

Clinical TrialsLymphoma

Lymphoma Clinical Trials

Browse 6,584 clinical trials for lymphoma. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1101-1120 of 6,584 trials

CompletedExtension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who…NCT01226472·Stanford, California UnknownModified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell MalignanciesThis study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating refractory/relapsed B-cell malignancies.NCT04684472·Chengdu, Sichuan CompletedRituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/LymphomaThe goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small…NCT00669877·Houston, Texas Enrolling by invitationLong-term Follow-up of Patients Treated With Genetically Modified Autologous T CellsLong-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.NCT03628612·Miami, Florida and 8 others

Related Searches

hodgkintrials non-hodgkintrials

Data from ClinicalTrials.govTerms

UnknownClinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)An open-label, single-arm, phase II clinical study of anti-PD-1 antibody GB226 in treatment of recurrent or refractory B-cell non-Hodgkin's lymphoma (B-NHL)NCT03639181·Beijing, Beijing Municipality

WithdrawnAcalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaThis phase Ib/II trial studies the side effects of acalabrutinib and duvelisib and how well they work in treating patients with indolent non-Hodgkin lymphoma that has come back…NCT04836832

RecruitingA Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular LymphomaThe purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any…NCT05389293·Washington D.C., District of Columbia and 8 others

RecruitingCo-administration of CART22-65s and huCART19 for B-ALLThis study will evaluate the safety and efficacy of administering two CAR T cell products, huCART19 and CART22-65s, in children with advanced B cell Acute Lymphoblastic Leukemia…NCT05674175·Philadelphia, Pennsylvania

RecruitingA Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological MalignanciesThis is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R)…NCT06703892·Taipei

RecruitingA Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesThe main aims of this 2-part study are: * Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple…NCT05908409·Santander, Cantabria and 10 others

Enrolling by invitationA Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic MalignanciesThis study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY035 cell injection in the…NCT07784309·Tianjin

CompletedMobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma PatientsPatients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) will be mobilized with chemotherapy and G-CSF plus plerixafor (AMD3100).NCT00322387·Duarte, California and 4 others

CompletedA Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3aThis multi-center, open-label, randomized study will evaluate the participant preference with subcutaneous versus intravenous administration of MabThera/Rituxan (rituximab) in…NCT01724021·Buenos Aires and 245 others

TerminatedAntineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's LymphomaCurrent therapies for Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma provide very limited benefit to the patient.NCT00003501·Houston, Texas

TerminatedTherapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood Cell Transplantation Following Chemotherapy.Given the poor prognosis of HIV-associated non-Hodgkin's lymphoma (NHL) and it's still high incidence in HAART era, more intensive therapy is required in patients with initially…NCT00432419·Créteil

CompletedDose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic MalignanciesThe purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.NCT00710528·Palo Alto, California and 8 others

RecruitingAssessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceThe purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.NCT07132567·Busan, Busan Metropolitan City and 5 others

UnknownObservation in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Treated on Clinical Trial CAN-NCIC-LY9RATIONALE: Treatment for diffuse large B-cell non-Hodgkin's lymphoma may cause side effects and secondary cancers later in life.NCT00400907

UnknownTreatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell TherapyThis is a single arm, open-label, phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T, an autologous tri-functional anti- CD19 chimeric antigen receptor…NCT03720496·Haikou, Hainan

UnknownAllogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) PatientsThis study aims to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells obtained from a blood-related donor of patients with relapsed or…NCT04696705·Tianjin, Tianjin Municipality

PreviousPage 56 of 330Next